| Wiskott-Aldrich Syndrome

Gammagard Liquid vs Gammaplex

Side-by-side clinical, coverage, and cost comparison for wiskott-aldrich syndrome.

Deep comparison between: Gammagard Liquid vs Gammaplex with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGammaplex has a higher rate of injection site reactions vs Gammagard Liquid based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Gammaplex but not Gammagard Liquid, including UnitedHealthcare

Category

Gammagard Liquid

Gammaplex

At A Glance

RouteIV infusion or SC injection

FrequencyEvery 3-4 weeks (IV) or weekly (SC)

ClassImmune globulin replacement

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassImmune globulin (IgG replacement)

Indications

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Congenital agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency
Multifocal motor neuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Congenital agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency
Immune thrombocytopenic purpura

Dosing

Primary Immunodeficiency (IV) 300-600 mg/kg every 3-4 weeks by IV infusion; start at 0.5 mL/kg/hr, increase every 30 minutes if tolerated up to 5 mL/kg/hr.

Primary Immunodeficiency (SC) Initial dose 1.37 x previous IV dose divided by weeks between IV doses, given weekly; 20-30 mL/site at 20-30 mL/hr/site (>=40 kg) or 20 mL/site at 15-20 mL/hr/site (<40 kg).

Multifocal Motor Neuropathy 0.5-2.4 g/kg/month by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.

Chronic Inflammatory Demyelinating Polyneuropathy Induction 2 g/kg divided over 2-5 consecutive days, then maintenance 1 g/kg divided over 1-4 consecutive days every 3 weeks by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.

Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-800 mg/kg (3-8 mL/kg) IV every 3-4 weeks; initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.

Immune thrombocytopenic purpura 1 g/kg (10 mL/kg) IV on 2 consecutive days (total dose 2 g/kg); initial infusion rate 0.5 mg/kg/min for 15 minutes, then increase gradually every 15 minutes to 8 mg/kg/min.

Contraindications

Anaphylactic or severe systemic hypersensitivity to human immune globulin
IgA deficiency with antibodies to IgA and history of hypersensitivity

Previous anaphylactic or severe systemic reaction to human immune globulin
IgA deficiency with antibodies to IgA and a history of hypersensitivity

Drug Interactions

162View drug interactions

Adverse Reactions

Most common (>=5%) - Primary Immunodeficiency (IV) Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, edema peripheral, pruritus, cardiac murmur

Most common (>=5%) - Primary Immunodeficiency (SC) Infusion site events, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, pain in extremity

Most common (>=5%) - Multifocal Motor Neuropathy Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, pain in extremity

Most common (>=5%) - Chronic Inflammatory Demyelinating Polyneuropathy Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, pain in extremity

Serious Aseptic meningitis (IV for PI), pulmonary embolism, blurred vision (MMN)

Postmarketing Hemolysis, anaphylactic shock, cerebrovascular accident, transient ischemic attack, tremor, myocardial infarction, deep vein thrombosis, hypotension, pulmonary embolism, pulmonary edema, hyperhidrosis, chest pain, transfusion-related acute lung injury, hypersensitivity, myalgia, chills

Most common (>=5%) in PI Headache, migraine, pyrexia

Most common (>=5%) in ITP Headache, vomiting, pyrexia, nausea, arthralgia, dehydration

Serious Thrombotic events, hemolysis; in ITP subjects: headache, vomiting, dehydration

Postmarketing Tachycardia, thromboembolism, hypertension, flushing, nausea, chills, chest discomfort, pyrexia, back pain, polymyositis, headache, dyspnea, rash, urticaria

Pharmacology

GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents and contains antibodies that interact with immune system cells; the mechanism in CIDP may include immunomodulatory effects.

Polyclonal human IgG that provides replacement therapy for primary humoral immunodeficiency via a broad spectrum of opsonic and neutralizing IgG antibodies against pathogens and their toxins through antigen binding and effector functions; the mechanism of action in both PI and ITP has not been fully elucidated.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Gammagard Liquid